$7.50
arrow_drop_down1.83%Key Stats | |
---|---|
Open | $7.59 |
Prev. Close | $7.64 |
EPS | -7.41 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 7.43 | 7.71 |
52 Week Range | 7.43 | 28.26 |
Ratios | |
---|---|
EPS | -7.41 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
SAGE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics
SAGE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) INVESTOR ALERT: Investors With Large Losses in Sage Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm